ClinicalTrials.gg
RecruitingNCT07166042Med-RT BGUpdated Nov 17, 2026

Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies

A Phase 3 interventional study of 10-15 minute, Audio-Recorded Guided Mediation Practices in Breast Cancer and Gynecologic Cancer, sponsored by University of Utah. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Utah · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 17, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Breast Neoplasms by University of Utah — 9 open to participants now, 9 under way, 1 of them phase 3. Breast Neoplasms · University of Utah.

Planned enrollment
17th of 33
34 · median 34
Started
2025
with 7 others
Phase 3
2 of 33
1 open now
Registered
31st of 33
by date

Among the 33 studies in Breast Neoplasms by University of Utah, this one is the 17th largest by planned enrollment, is one of 8 that started in 2025, is one of 2 in phase 3, and was the 31st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 33 studies in Breast Neoplasms by University of Utah are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Breast Neoplasms by University of Utah, or all of them as a file.
02

Study summary

The goal of this study is to assess the effect of brief mindfulness-guided meditations during radiation therapy (RT) for patients with anxiety related to RT for breast and gynecological cancers.

03

Conditions studied

  • Breast Cancer
  • Gynecologic Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant aged ≥ 18 years.
  • Diagnosis of breast or gynelogical cancer.
  • Eligible to receive 15-25 daily radiation therapy treatments for breast or gynelogical cancer.
  • Willing to participate in either the guided meditation or standard of care control arm, regardless of treatment assignment.
  • performance score ≥ 60 or performance score ≤ 2.
  • Able to provide and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  • Active suicidal ideation or active psychotic state in the opinion of the investigator.
  • Patient is receiving deep inspiration breath hold treatment.
  • An unstable illness that, in the opinion of the investigator, would interfere with study treatment.
  • Prior radiation therapy.
  • Inability to understand and/or speak the English language.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Guided Meditation Intervention

    Behavioral: 10-15 minute, Audio-Recorded Guided Mediation Practices

  • No intervention
    Standard of Care

Interventions

  • Behavioral10-15 minute, Audio-Recorded Guided Mediation Practices

    The 5 mindfulness practices, all of which have been validated in prior research. Body Scan practice will consist of how to direct non-judgmental attention to different regions of the body The Mindful Breathing practice will consist of focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and body sensations. The Mindfulness of Discomfort practice will consist of instruction in how to "zoom in" to deconstruct discomfort and precisely map each feelings' spatial location, use mindful breathing to "zoom out" and broaden the field of awareness to include neglected sensory elements, and shift attention from unpleasant feelings to neutral/pleasant sensations or experiences. The Savoring practice will consist of instruction in identifying and amplifying pleasant memories. The Loving-Kindness practice will consist of instruction in cultivating feeling of warmth and compassion toward the self and others.

06

What researchers measure

Primary outcomes

  1. Change in acute anxiety in participants receiving mindfulness intervention during RT compared to standard of care control conditions.

    To assess the acute anxiolytic effects of a brief mindfulness intervention during radiation therapy (RT) for patients with anxiety related to RT for breast and gynecological cancers. Acute anxiety during RT will be measured at each treatment visit with an individual item ("How nervous, anxious or on edge do you feel right now?" scored on a 0 (not at all) to 10 (Very much). derived from the Generalized Anxiety Disorder 2-item (GAD-2) scale, measured before and after RT. The change from before to after RT will be averaged over all treatment visits.

    Time frame: 7 weeks

Secondary outcomes

  1. Change in anxiety in everyday life in participants receiving mindfulness intervention during RT compared to standard of care control conditions.

    To assess the distal anxiolytic effects of a brief mindfulness intervention during RT for patients with anxiety related to RT for breast and gynecological cancers. Anxiety in everyday life will be measured using the total score of the Generalized Anxiety Disorder 2-item (GAD-2) scale prior to RT (minimum value 0, maximum value 6, score of 3 or higher considered clinical). This will be measured once a week during RT.

    Time frame: 7 weeks

  2. Change in anxiety during RT and in everyday life as measured by the modified MPoD

    To determine whether the brief mindfulness intervention during RT increases patients' state mindfulness and whether the degree of changes in state mindfulness during RT predict decreases in acute anxiety and anxiety in daily life. Modified Metacognitive Processes of Decentering Scale (MPoD) consists of 4 items scored on a 0-10 scale, "0" meaning "Not at All" and "10" meaning "Very Much".

    Time frame: 7 weeks

  3. Change in self transcendence and the magnitude/degree of increased self transcendence will predict degree of anxiety in the course of daily life as measured by total score of the Nondual Awareness Dimensional Assessment (NADA).

    To determine whether the brief mindfulness intervention during RT increases patients' self transcendence and whether the degree of changes in self-transcendence during RT predict decreases in anxiety in daily life. The NADA will ask patients to rate their feelings 15 minutes before and after treatment on a scale of 0 (not at all) to 10 (very much).

    Time frame: 7 weeks

Other outcomes

  1. To assess the change in quality of life, anxiety and depression between the experimental and control arm over an extended time period using the WHOQLC-2, GAD-2 and PHQ-2

    Change in quality of life, anxiety and depression in everyday life in participants receiving mindfulness intervention during RT compared to standard of care control conditions. Quality of life will be measured using the WHOQOL-2 survey. Anxiety will be measured using the GAD-2 survey. Depression will be measured using the PHQ2 survey. This will be measured prior to starting radiation therapy and at their 3 month follow up visit.

    Time frame: 7 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 24 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start Sep 2025 → Nov 2025, primary completion Sep 2027 → Nov 2027 and completion Sep 2028 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2025
First posted
Sep 10, 2025
StartActual
Nov 4, 2025was Sep 2025
Primary completionEst.
Nov 2027was Sep 2027
CompletionEst.
Nov 2028was Sep 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 25, 2025→Nov 4, 2025
Nov 17, 2026
Primary completion
Sep 30, 2027→Nov 2027
Nov 17, 2026
Study completion
Sep 30, 2028→Nov 2028
Nov 17, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • Addedother outcomeTo assess the change in quality of life, anxiety and depression between the experimental and control arm over an extended time period using the WHOQLC-2, GAD-2 and PHQ-2Time frame: 7 months
Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Huntsman Cancer Institute at University of Utah · Salt Lake City, United StatesContact added (no phone or email listed)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Start date Sep 25, 2025→Nov 4, 2025
    Primary completion Sep 30, 2027→Nov 2027
    Study completion Sep 30, 2028→Nov 2028
    Secondary outcomes 1 added
    What changed in the outcomes
    • Addedother outcomeTo assess the change in quality of life, anxiety and depression between the experimental and control arm over an extended time period using the WHOQLC-2, GAD-2 and PHQ-2Time frame: 7 months
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Huntsman Cancer Institute at University of Utah · Salt Lake City, United StatesContact added (no phone or email listed)
    + 3 other changes: identifiers, verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07166042
Lead sponsor
University of Utah
Collaborators
Huntsman Cancer Institute
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Nov 4, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Rachel R. Kingford
Contact
rachel.kingsford@hci.utah.edu
801-585-0115
Lindsay Burt, MD
principal investigator · Huntsman Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion